新兴生物药
弹性解决方案响应队betway必威怎么提款数据驱动洞见
-
美洲
-
亚洲和大洋洲
-
-
中东和非洲
区域划分
- 美洲
- 亚洲和大洋洲
- 欧洲
- 中东和非洲
求解法
- 研发
- 真实世界证据
- Commercialization
- 安全调控遵章
- 必威官方在线
生命科学单元
必威手机APP保健单元
问题区
原创创创作
- 连通情报
- 必威手机APP保健级AI
- b必威人文数据云
- IQVIA创新中心
- 分散试播
- 病人体验苹果驱动
何为我们
新闻资源
Livre白朗
通向快速批注的不同路径
初始阶段肿瘤学研究中拥抱创新设计
2019年2月01
导 言
科技进步加上未满足病人需求正在加速时间和创造方法开发肿瘤药包括无缝临床试验策略需要不同于传统路径的思维方式
科技进步加之未满足病人需求,驱动加速时间和创造药法开发路径可理解地保持高水平,而精密医学和免疫代谢成就改变了目标Researchers and clinicians want to develop transformative medicines with less toxicity than traditional chemotherapies that curtail progression of cancers and their recurrences, if not eradicate them. With such treatments in mind, oncology sponsors and regulators alike seek new ways to efficiently move promising therapies from the clinic to approval, and have started to embrace a seemingly seamless path that bypasses the traditional development paradigm of stand-alone sequential Phase I, II and III trials. Today, when sponsors see strong responses during early development, they may consider a faster path to approval via single-arm studies or early phase expansion cohort trials conceived to gather pivotal data. Regulatory authorities have embraced these innovative approaches. As a specialty oncology clinical research organization, IQVIA™ Biotech counsels sponsors considering these routes to consider several aspects during protocol design to ensure the best way forward, including how a seamless clinical trial strategy requires a different mindset than traditional pathways.
下载阅读更多
相关解决方案
肿瘤学
以病人为中心开发生态学,管理试验复杂性并增加可预测性和速度